SRTAHIGH SIGNALOPERATIONAL10-K

SRTA has undergone a complete business transformation from Blade Air Mobility (passenger aviation) to Strata Critical Medical (time-critical healthcare logistics), representing a fundamental pivot in business model and market focus.

This represents a dramatic strategic shift from a passenger aviation company developing electric vertical aircraft technology to a specialized medical logistics provider focused on organ transport and healthcare services. The company has completely repositioned itself in a different industry with different risk profiles, regulatory environments, and growth prospects, requiring investors to reassess the investment thesis entirely.

Comparing 2026-03-03 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

Despite the massive business transformation, financial performance shows mixed but generally positive trends with net income swinging dramatically positive from -$27.3M to +$41.3M, gross profit growing 39% to $41.1M, and cash position strengthening 68.5% to $31.0M. However, operating cash flow deteriorated significantly from -$2.5M to -$48.9M, suggesting potential working capital challenges or timing differences, while the 85% increase in accounts receivable and 34% rise in total liabilities indicate the company is managing higher volumes but with extended collection cycles. The overall picture suggests a growing business with improved profitability but concerning cash flow dynamics that warrant close monitoring.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-1841.8%
-$2.5M-$48.9M

Operating cash flow fell 1841.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
+251.4%
-$27.3M$41.3M

Net income grew 251.4% — bottom-line growth signals improving overall business health.

Accounts Receivable
Balance Sheet
+85.1%
$21.6M$40.0M

Receivables surged 85.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
-68.9%
$30.9M$9.6M

Capex reduced 68.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+68.5%
$18.4M$31.0M

Cash position surged 68.5% — strong cash generation or capital raise providing significant financial cushion.

Gross Profit
P&L
+39%
$29.6M$41.1M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Income
P&L
+34.1%
-$33.9M-$22.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
+33.6%
$34.7M$46.4M

Liabilities grew 33.6% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Assets
Balance Sheet
+26.8%
$256.7M$325.5M

Asset base grew 26.8% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+25.7%
$221.9M$279.1M

Equity base grew 25.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-13
ADDED
They appear in several places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which we operate.
Risks Related to Intellectual Property, Cybersecurity, Information Technology and Data Management Practices interruptions, defects, failures or vulnerabilities in our technology systems or those of third-party providers; cybersecurity incidents, data breaches or misuse of artificial intelligence technologies that could disrupt operations or expose sensitive information; our ability to protect and enforce intellectual property rights; and risks associated with our use of open-source software.
Legal and Regulatory Risks Related to Our Business our operations within highly regulated aviation, healthcare and transplant environments, including evolving federal, state and local laws and regulations; the impact of any litigation or regulatory investigations that we may be subject to; our ability to comply with privacy, data protection, consumer protection and security laws; and the expansion of environmental regulations.
Other Risks our ability to remediate any material weaknesses or maintain effective internal controls over financial reporting; our ability to maintain effective disclosure controls and procedures; and the other factors described elsewhere in this Annual Report, included under the headings Risk Factors, Management s Discussion and Analysis of Financial Condition or as described in the other documents and reports we file with the SEC.
Unless the context indicates otherwise, references in this Annual Report on Form 10-K to the Company , Strata , we , us , our , and similar terms refer to Strata Critical Medical, Inc.
+7 more — sign up free →
REMOVED
They appear in several places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies, the markets in which we operate and the development of Electric Vertical Aircraft ( EVA ) technology.
Unless the context indicates otherwise, references in this Annual Report on Form 10-K to the Company , Blade , we , us , our , and similar terms refer to Blade Air Mobility, Inc.
( Blade or the Company ) provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe.
Based in New York City, Blade s asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft ( EVA or eVTOL ), enabling lower cost air mobility that is both quiet and emission-free.
Blade currently operates in three key product lines across our Passenger and Medical segments: Passenger segment Short Distance Consisting primarily of helicopter and amphibious seaplane flights in the United States and Europe between 10 and 100 miles in distance.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →